

## RESEARCH ARTICLE

# Transversal sero-epidemiological study of *Bordetella pertussis* in Tehran, Iran

Gaelle Noel<sup>1</sup>, Farzad Badmasti<sup>2</sup>, Vajihe S. Nikbin<sup>2</sup>, Seyed M. Zahraei<sup>3</sup>, Yoann Madec<sup>4</sup>, David Tavel<sup>4</sup>, Mohand Ait-Ahmed<sup>5</sup>, Nicole Guiso<sup>1</sup>, Fereshteh Shahcheraghi<sup>2‡</sup>, Fabien Taieb<sup>1,4‡\*</sup>

**1** Institut Pasteur, Center for Translational Research, Paris, France, **2** Department of Bacteriology, Pertussis Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran, **3** Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran, **4** Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France, **5** Institut Pasteur, Centre for Translational Science, Clinical Coordination, Paris, France

☞ These authors contributed equally to this work.

‡ FS and FT also contributed equally to this work.

\* [fabien.taieb@pasteur.fr](mailto:fabien.taieb@pasteur.fr)



## OPEN ACCESS

**Citation:** Noel G, Badmasti F, Nikbin VS, Zahraei SM, Madec Y, Tavel D, et al. (2020) Transversal sero-epidemiological study of *Bordetella pertussis* in Tehran, Iran. PLoS ONE 15(9): e0238398. <https://doi.org/10.1371/journal.pone.0238398>

**Editor:** Abdallah M. Samy, Faculty of Science, Ain Shams University (ASU), EGYPT

**Received:** March 20, 2020

**Accepted:** August 15, 2020

**Published:** September 1, 2020

**Peer Review History:** PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0238398>

**Copyright:** © 2020 Noel et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the manuscript and its Supporting Information files.

**Funding:** The author(s) received no specific funding for this work.

## Abstract

### Objectives

Pertussis remains endemic despite high vaccine coverage in infants and toddlers. Pertussis vaccines confer protection but immunity wanes overtime and boosters are needed in a life-time. Iran, eligible for the Expanded Program on Immunization that includes the primary immunization, implemented two additional booster doses using a whole-cell vaccine (wPV) at 18 months-old and about 6 years-old. Duration of protection induced by the wPVs currently in use and their impact as pre-school booster are not well documented. This study aimed at assessing vaccination compliance and at estimating the duration of protection conferred by vaccination with wPV in children aged < 15 years in Tehran, Iran.

### Methods

Detailed information on vaccination history and capillary blood samples were obtained from 1047 children aged 3–15 years who completed the 3 doses-primary pertussis immunization, in Tehran. Anti-pertussis toxin IgG levels were quantified by ELISA.

### Results

Compliance was very high with 93.3% of children who received the three primary and 1<sup>st</sup> booster doses in a timely manner. Timeliness of the 2<sup>nd</sup> booster was lower (63.3%). Rate of seropositive samples continuously and significantly increased from 1–2 to 5–6 years after 1<sup>st</sup> booster attaining 30.4% of children exhibiting serological sign of recent contact with *B. pertussis*. Second booster dating back 1 or 2 years was associated with high antibody titers, which significantly decreased within 3 years from injection. Among children who received 2<sup>nd</sup> booster injection more than 2 years before serum analysis, seroprevalence of pertussis infection was 8.4% and seropositivity rate was higher from the 10 years-old group.

**Competing interests:** The authors have declared that no competing interests exist.

## Conclusion

Seropositivity in children aged 6–7 years with no 2<sup>nd</sup> booster supports the need for a vaccination at that age. Adolescent booster may also be considered.

## Introduction

Pertussis, also known as whooping cough, is a highly contagious disease that remains a major cause of morbidity and mortality in infants worldwide despite vaccination [1]. The etiological agent, *Bordetella pertussis*, is a Gram-negative human-restricted bacterial pathogen that is transmitted through droplets and causes a prolonged respiratory disease that is frequently fatal in young infants.

In an effort to fight the disease, whole-cell pertussis vaccines (wPVs), made of chemically or heat-inactivated bacterium, were developed and vaccination was introduced in the 1950s and largely distributed to low- and middle-income countries (LMICs) by the Expanded Program on Immunization (EPI) since the 1970–80s. Generalized vaccination has greatly reduced pertussis burden [1, 2] but has also modified pertussis epidemiology. Adolescents and adults became new reservoirs for a disease formerly believed to be pediatric, threatening newborns too young to have completed their primary immunization [1, 3]. This was mainly due to waning immunity after vaccination with wPV, as well as after natural infection and several studies reported a duration of protection induced by primary vaccination and one booster of 5 to 10 years [4–6]. Today most high-income countries have replaced wPVs with less reactogenic acellular pertussis vaccines (aPVs) for primary immunization and booster doses, while many LMICs still use the less expensive wPVs provided through the EPI, often limiting their vaccination program to primary immunization in infants [1, 7].

wPVs may suffer from disparities in production processes [1], and studies performed on wPVs available in 1980s and 1990s showed large heterogeneity associated to highly variable immunogenicity and efficacy [8]. Importantly, information is scarce about more recently produced wPVs currently used in LMICs.

*B. pertussis* is still endemic and most recent estimates indicate that around 24 million cases and 160 000 deaths from pertussis still occurred in children younger than 5 years of age in 2014 around the world, despite high, although <90%, vaccine coverage [2, 9]. However, surveillance of the disease is rarely implemented in LMIC and these numbers are probably underestimated [7].

Iranian pertussis immunization schedule, that partially relies on EPI, includes 3 primary doses (at 2, 4 and 6 months of age) and two booster injections at 18 months and in pre-school children using a trivalent diphtheria tetanus whole-cell pertussis combined vaccine (DTwP) [10]. Pertussis vaccines locally manufactured by Razi Vaccine and Serum Research Institute were replaced by vaccines licensed by the Serum Institute of India (SII) in 2007, and since 2014, the trivalent diphtheria tetanus wP combined vaccine (DTwP) is restricted for boosters while the pentavalent diphtheria tetanus wP *Haemophilus influenzae* hepatitis B combined vaccine (DTwP-Hib-HepB) is given for primary immunization. Immunogenicity and duration of protection induced by these specific vaccines is unknown [11–13]. In addition to quality of the vaccine, completion (i.e. number of doses) and compliance (i.e. age at injection) with recommended immunization schedule impact vaccine effectiveness. In Iran, information about compliance with Iranian immunization schedule is poor, vaccine coverage is reported to be high with 1<sup>st</sup> and 3<sup>rd</sup> dose coverage over 95% since 1995, which is above global coverage estimated

to be around 85% for a 3-dose course of a pertussis-containing vaccine in 2017 [14]. Despite high coverage and delivery of booster doses, circulation of *B. pertussis* has been documented in Iran, mainly in children but also in adolescents and adults [15, 16]. Sero-surveillance data are scarce, and laboratory diagnosis aren't always obtained using the recommended technology. Accurate epidemiological data are needed to monitor and adapt current vaccination strategies.

Evaluating serological anti-pertussis toxin (PT) immunoglobulin-G (IgG) levels is a straightforward and cost-effective way of estimating occurrence of infection by *B. pertussis* [17–20]. This study aimed at applying this method to evaluate circulation of *B. pertussis* and duration of protection induced by wPV in children 3–15 years of age in Tehran, and at assessing compliance with national recommendations.

## Methods

### Study population and design

The study was implemented in 15 centers in Tehran, Iran (9 kindergartens, 4 primary schools, 1 medium school and 1 medium/high school), between December 2016 and February 2017. In order to recruit in centers representative of Tehran schools, a random selection was performed from the list of schools provided by the Ministry of Education in 6 municipality districts also randomly selected among the 22 existing in this province. Enrollment criteria were: being aged 3 to 15 years, having completed pertussis primary immunization (3 first injections) and owning detailed information about history of pertussis immunization. Three year old was chosen as lower limit of age for enrollment in the study to include children being at least a year away from 1<sup>st</sup> pertussis booster dose. Eight age groups were defined (3&4, 5&6, 7&8, 9, 10, 11, 12&13 and 14&15 years old). Date of birth, gender, pertussis immunization history obtained from record booklet from the child or from a copy from school (information required at school entry), and serology results were collected, filled in paper questionnaires and recorded in a computerized database. No information on recent history of pertussis or respiratory illness was collected.

### Pertussis immunization schedule analysis

Iranian pertussis vaccination schedule includes a 3 doses-primary immunization at 2, 4, and 6 months of age, and 2 booster doses. Recommended age for 1<sup>st</sup> booster dose is 18 months, recommended age for 2<sup>nd</sup> booster dose has varied over time and was 4–6 years before 2009, 6 years in 2009–2013 and is 5–6 years since 2014. Compliance with vaccination schedule was analyzed based on the national recommendations at time of vaccination, exact definition used was the following: having received the 1<sup>st</sup> dose at 2 months +/- 14 days, the 2<sup>nd</sup> and 3<sup>rd</sup> doses at 4 to 10 weeks interval from the previous dose, the 1<sup>st</sup> booster dose at 18 months– 2 / + 8 weeks and the 2<sup>nd</sup> booster dose at age [4–6], 6, or [5, 6] years when given in 2008, in 2009–2013, or in 2014–2016, respectively [21].

### Blood sample collection

One capillary blood sample (200–400 µl) was collected for each participant by a nurse using lancet needle (BD Sentry 23G, Becton Dickinson). Tubes were inverted several times, stored at 15–25°C and sent within 6 hours to the bacteriology laboratory at the Institut Pasteur of Iran in Tehran. At the laboratory, blood was immediately spun, and serum was stored at -20°C for later analysis. Quantitative assessment of anti-PT IgG was performed using a purified PT-containing Enzyme-linked immunosorbent assay (ELISA) kit (EUROIMMUN; reference EI 2050-G) [22], and the World Health Organization (WHO) reference serum available from the

National Institute for Biological Standards and Control (NIBSC). Results were expressed in International Units (IU)/ml. Lower limit of quantitation (LLOQ) was defined as 5 IU/ml.

### Serology analysis

Anti-PT IgG levels rapidly wane overtime and cut-off level of 40 IU/mL was used to identify seropositive individuals either following an immunization or, in absence of recent immunization, having had a contact with circulating bacteria sometime in the past year. Anti-PT IgG levels  $\geq 100$  IU/mL were also represented and, in the absence of recent vaccination, were interpreted as a sign of infection sometime in the past 6 months [17, 23, 24]. Duration of protection was evaluated by comparing proportions of positive individuals between i) age groups and ii) groups defined based on timespan since last vaccination among children who received either 4 or 5 injections.

### Statistical analysis

For description of continuous variables, the median, interquartile range (IQR), minimum and maximum were estimated. For categorical variables, percentages were estimated, and comparisons were conducted using the two-sided chi<sup>2</sup> or fisher exact test depending on the sample size. Logistic regression models were used to identify factors associated with anti-PT IgG  $\geq 40$  IU/ml. Statistical analyses were carried out using Stata 15 software. Differences were considered significant at  $p < 0.05$ .

### Ethical consideration and safety of participants

The study protocol was reviewed and approved by the Research Ethics Committee of Pasteur Institute of Iran. Informed written consent was obtained from all parents/legal guardians, and oral consent form was obtained from children aged over 7. Only participants who agreed to participate were included in the study. Authorization for data processing has been obtained from French legal authority (*Commission Nationale Informatique et Liberté* [CNIL]), and pseudonymization of names was performed assigning a code specific to the study to each participant.

## Results

### Study population description

A total of 1047 children were enrolled, and the number of children ranged from 96 to 176 in the different age groups (S1 Table). Enrolment took place over a 3-month period, and started in kindergartens enrolling youngest individuals and ended in high schools with the oldest children. In addition, boys and girls tended to be enrolled from distinct sites due to unisex schools. Thus, age had a strong collinearity with site, month of inclusion and gender.

All children received the 1<sup>st</sup> pertussis booster dose scheduled at 18 months of age. The 2<sup>nd</sup> pertussis booster had been received by 56/142 (39.4%) and 174/176 (98.9%) children belonging to the 5&6 and 7&8 age group, respectively, and all older children.

### Compliance with Iranian pertussis immunization schedule

**Compliance with recommended age or interval.** Overall median age at each of the injections matched with Iranian pertussis immunization schedule (Table 1).

Compliance with recommended age or intervals were analyzed for each dose (Fig 1). Regarding the primary immunization, no child received the 1<sup>st</sup> injection too early and only 15/1047 (1.4%) received it too late as compared to Iranian standards. Nearly all of those who had

**Table 1. Age description at pertussis vaccine injections.**

	Primary immunization doses			Boosters	
	1 <sup>st</sup> (m)	2 <sup>nd</sup> (m)	3 <sup>rd</sup> (m)	1 <sup>st</sup> (m)	2 <sup>nd</sup> (y)
Recommended age	2.00	4.00	6.00	18.00	[4–6] if <2009 6 if 2009–2013 [5–6] if >2013
median age	2.00	4.00	6.03	18.00	6.14
25%–75%	1.97–2.03	3.97–4.07	5.97–6.07	17.93–18.10	5.92–6.58
10%–90%	1.93–2.09	3.90–4.13	5.90–6.16	17.80–18.23	5.75–7.23
min—max	1.57–38.20	3.02–40.07	4.92–41.93	8.13–54.23	5.09–7.52
N	1047	1047	1047	1047	815


Values are presented in months (m) or years (y).

<https://doi.org/10.1371/journal.pone.0238398.t001>

received the 1<sup>st</sup> dose on time also received the 2<sup>nd</sup> and 3<sup>rd</sup> dose on time (1004/1047; 95.9%) and were therefore compliant with full course of primary immunization. Among those who were not timely vaccinated sometime in their primary immunization course (n = 43), only a minority of individuals received a 2<sup>nd</sup> or 3<sup>rd</sup> dose too early (1/43) or too late (27/43). All children with a delayed 1<sup>st</sup> or 2<sup>nd</sup> dose received the subsequent doses within correct intervals as national standards.

Regarding compliance with 1<sup>st</sup> booster, 1000/1047 (95.5%) children have received the 1<sup>st</sup> booster at the recommended age. Of note, among those who were late at 1<sup>st</sup> booster dose (n = 21), 16 (76.2%) respected a 12 months interval from the last primary immunization dose.

A total of 517/817 (63.3%) children received the second booster dose at the recommended age. Eligible children were those already vaccinated with that dose (n = 815) and unvaccinated children aged ≥ 7 (n = 2).



**Fig 1. Compliance with Iranian pertussis immunization schedule.** Numbers (n) and proportions (%) of children who received early (light grey), on time (white) or late (dark grey) their pertussis vaccine dose as compared to Iranian recommendations are shown for each injection. Respect to intervals in between 1<sup>st</sup> and 2<sup>nd</sup>, and 2<sup>nd</sup> and 3<sup>rd</sup> are shown with respect to compliance with 1<sup>st</sup> and 2<sup>nd</sup> dose, respectively. Days (d); weeks (w); years (y).

<https://doi.org/10.1371/journal.pone.0238398.g001>


**Compliance with entire immunization schedule.** Overall, 702/1047 (67.1%) children were vaccinated in a timely manner (including 4 or 5 injections based on the child age), and 977/1047 (93.3%) children received the 3 primary doses and 1<sup>st</sup> booster in a timely manner.

## Serological analysis

**Description of anti-PT IgG levels.** Anti-PT IgG titers were determined for 1010 serum samples. Other 37/1047 samples were not tested due to low volume or hemolysis. Proportion of children with high IgG titers was significantly higher in 5&6 and 7&8 age groups, corresponding to recommended age for receiving 2<sup>nd</sup> booster dose.

**Anti PT IgG level in individuals who did not received the 2<sup>nd</sup> booster.** Among the study population tested for anti-PT IgG, 226/1010 (22.4%) children were not vaccinated with 2<sup>nd</sup> booster. Their anti-PT IgG levels were evaluated with respect to timespan since 1<sup>st</sup> booster dose. Shortest timespan since 1<sup>st</sup> booster injection was 17.9 months. Level of antibodies was associated to and increased with the delay since 1<sup>st</sup> booster injection categorized in year (Fig 2 and Table 2). Overall, time since 1<sup>st</sup> booster was significantly associated with higher anti-PT IgG titers (global  $p = 0,007$ ). Rate of seropositive children among those who received the 1<sup>st</sup> booster dose 5 to 6 years before blood testing was significantly higher as compared to those who received their booster within 1 to 2 years, 7/23 (30.4%) and 1/42 (2.4%), respectively (Table 2;  $p = 0.009$ ). These individuals were 6.5–7.0 years old. Antibody levels were not associated to compliance of these individuals with the primary and 1<sup>st</sup> booster dose schedule (Table 2).

**Anti-PT IgG levels related to 2<sup>nd</sup> booster.** A total of 784/1010 (77.6%) children had already received the 2<sup>nd</sup> booster dose. The proportion of individuals with anti-PT IgG  $\geq 40$  IU/ml was high among those who received the 2<sup>nd</sup> booster within a year and within 1–2 years



**Fig 2. Distribution of anti-PT IgG levels by timespan since 1<sup>st</sup> booster among individuals who received 4 injections.** Timespans were categorized by year.

<https://doi.org/10.1371/journal.pone.0238398.g002>

Table 2. Distribution of positive individuals by timespan since 1<sup>st</sup> booster dose among individuals who received 4 injections.

		N	anti-PT IgG $\geq$ 40 IU/ml n (%)	OR (95% CI)	p	global p
Timespan from 1st booster (years)	[1-2[	42	1 (2.4)	1	-	0.007
	[2-3[	73	5 (6.9)	3.0 (0.3–26.7)	0.322	
	[3-4[	47	6 (12.8)	6.0 (0.7–52.1)	0.104	
	[4-5[	41	6 (14.6)	7.0 (0.8–61.2)	0.077	
	[5-6 [	23	7 (30.4)	17.9 (2.0–157.7)	0.009	
Compliance (Iranian standards)	no	10	1 (10.0)	1	-	na
	yes	216	24 (11.1)	1.1 (0.1–9.3)	0.913	
	Total	226	25 (11.1)			

<https://doi.org/10.1371/journal.pone.0238398.t002>

(27.7% and 32.5%, respectively), and significantly decreased among children vaccinated since 2–3 years (11.1%) (S2 Table).

**Anti-PT IgG levels related to infection post-2<sup>nd</sup> booster.** To distinguish infection- from vaccine-induced anti-PT IgG, analysis of proportion of children with anti-PT IgG  $\geq$  40 IU/ml was performed only in children whose 2<sup>nd</sup> booster injection was dating back  $>$ 2 years (n = 621). Proportions of children were calculated based on age groups and antibody level cut-offs (Fig 3). Infection-related seroprevalence (anti-PT IgG  $\geq$  40 IU/ml) was 8.4% in this population. Children aged 9 years showed the lowest proportion of anti-PT IgG (2.4%) (Table 3). Proportion of seropositive individuals was higher in 7&8 (15.3%;  $p = 0.004$ ), 10 (10.0%;  $p = 0.023$ ), 11 (10.5%;  $p = 0.018$ ) and 14&15 (10.0%;  $p = 0.026$ ) age groups. Compliance with Iranian pertussis immunization standard was not associated to serology (Table 3).




Fig 3. Distribution of anti-PT IgG levels by age groups among fully vaccinated individuals since  $>$ 2 years.

<https://doi.org/10.1371/journal.pone.0238398.g003>



Table 3. Risk factors associated to positive serology among fully vaccinated individuals since &gt; 2 years.

		N	anti-PT IgG $\geq$ 40 IU/ml n (%)	OR (95% CI)	p	global p
Age group (years)	7&8	59	9 (15.3)	7.3 (1.9–27.9)	0.004	0.035
	9	124	3 (2.4)	1	-	
	10	120	12 (10.0)	4.5 (1.2–16.3)	0.023	
	11	124	13 (10.5)	4.7 (1.3–17.0)	0.018	
	12&13	94	5 (5.3)	2.3 (0.5–9.7)	0.271	
	14&15	100	10 (10.0)	4.5 (1.2–16.8)	0.026	
Compliance (Iranian standards)	no	313	23 (8.3)	1	-	na
	yes	308	26 (8.4)	1.0 (0.6–1.8)	0.988	
	Total	621	52 (8.4)			

<https://doi.org/10.1371/journal.pone.0238398.t003>

## Discussion

This study aimed at evaluating age-specific distributions of anti-PT IgG in Iranian children for whom few data exist. This is the first sero-epidemiological study in children who received a pertussis vaccination that includes a booster injection, using a whole cell vaccine, at the age of 6 years.

Completion (i.e. having received all recommended doses) and compliance (i.e. having received recommended doses in a timely manner) are critical for maximizing vaccination effectiveness [1]. The delivery of 3 primary doses of wPV in children less than 12 months of age has been continuously increasing in Iran since EPI implementation in 1984 [21, 25]. The Iranian national monitoring system estimate coverage to be 95% since 1995 for dose 1 and 3, and coverage with the 1<sup>st</sup> booster dose to be 98–99% since 2014 [25, 26]. To our knowledge, no data report coverage of the 2<sup>nd</sup> booster dose yet. Our study does not give insight into proportion of children having incomplete primary immunization since receiving these 3 doses was part of our inclusion criteria. However, we observed that all participants received the 1<sup>st</sup> booster dose and 99.8% (1045/1047) of them were fully vaccinated by the age of 7.5 years. These data tend to show that once a child starts its pertussis immunization program, he/she successfully receives all five recommended doses. Our study also showed that 95.9% of the children, timely received the 3 primary doses, and compliance at 1<sup>st</sup> and 2<sup>nd</sup> booster injections was 95.5% and 63.3%, respectively. However, it should be noted that 2<sup>nd</sup> booster vaccination in Iran is performed at school entry which could explain short delays based on the month of the year the child was born.

Compliance observed herein was substantially higher than what has been reported so far in Iran. A study performed on 3610 children living in suburbs of five Iranian megalopolises, reported that 34.9%, 25.0%, 17.7% and 2.7% of children were vaccinated on time with 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> injections, and 1<sup>st</sup> booster, respectively; not vaccinated children represented <5% for each dose [27]. Data from another province than Tehran indicated that about 55% of children were timely vaccinated with the injection 1, 2 or 3, with a coverage greater than 99% [28]. Compliance definition used in these studies was slightly different to the one used herein, but, when applied to our data, did not significantly impact the result. However, this study may represent highly compliant sub-population as only children having completed the primary immunization, living in Tehran, attending school and owning their vaccination record booklet were considered. Also, socio-economic and spatial disparities are known as determinants of vaccine coverage and compliance and may contribute in part to result diversity across these studies [27, 29, 30].



Duration of protection induced by the SII vaccine distributed in Iran is unknown and may differ from wPVs from other manufacturers [31]. Detection of high antibody titers at distance from vaccination has been used to indirectly identify a contact with *B. pertussis* bacteria [1, 24].

Among subjects who received primary vaccinations and one booster only, a significant increase in sero-positivity rate was evidenced at 5–6 years from 1<sup>st</sup> booster injection, evidencing waning immunity since last vaccination. The duration of protection conferred by 3 doses—primary and a 18 months-booster vaccination with Sanofi Pasteur wPV used in France in the past was defined as 9 years [6, 32]. However, data from Russia and The Gambia, using different wPV, evidenced increasing risk of infection at around 6 years old in vaccinated individuals receiving the same number of doses, such as herein, underlining the importance of 6 years old-booster in controlling infections in children aged 5 to 7, as recommended by WHO [1, 18, 20].

We observed higher anti-PT IgG titers in children who received the 2<sup>nd</sup> booster within 2 years. Anti-PT IgG thereafter rapidly decreased to reach significantly lower levels in individuals who were 3 years from their last vaccination. An important pitfall in pertussis serology is that it is impossible to differentiate vaccine induced anti-PT IgG titers to those induced by natural infection. However, our results suggest substantial immunogenicity of the vaccine and an antibody decay from vaccination over a 2 years period. Although variability exists, previous studies evaluating other wPVs used for primary and one 18 months-booster injection suggest that immune responses to PT after vaccination are negligible or reach low levels within a year [33–37]. In Iran, an additional wPV booster at 6 years of age, rarely implemented in LMIC, is performed and humoral response to a 2<sup>nd</sup> booster is unknown. The 2 years-period from vaccination to antibody decay observed herein may indicate that this second booster promotes higher persistence of anti-PT IgG. Monitoring of anti-PT IgG kinetic following 6 years old-wPV booster injection would be suitable.

Among children who received two vaccine boosters, serological sign of contact with *B. pertussis* in the past year was the lowest in the 9 years old age group and was higher thereafter ranging from 2.4% to 15.3% (Fig 3 and Table 3). These observations may indicate greater susceptibility to pertussis in adolescents. Overall number of seropositive individuals was low but demonstrated the presence of *B. pertussis* circulation among these children. During the study period, Iranian CDC reported a total of 239 and 271 suspected cases in Tehran in 2016 and 2017, respectively (unpublished data). Age information was not available, however among 347 patients for whom nasopharyngeal samples were collected during the period 2004–2008 in 18 different provinces for performing pertussis diagnosis, 82% were <6 years old and only 43 were older patients for whom only 4 were confirmed positive by PCR [16]. This may reflect, at least in part, the difficulty in identifying suspected cases in older children and adults that may be caused by the milder pertussis syndrome in infected individuals of that age.

The implementation of an additional booster in adolescents may further contribute to reduce pertussis incidence in vaccinated population and lead to a shift in age of susceptible individuals. However, its impact on decreasing morbidity and mortality in infants < 1 year old, the most vulnerable population, might be limited. For this purpose, maternal immunization and the “cocooning” are two alternative strategies being recommended in countries using the wPV [1, 38]. Whatever the strategy, the availability of an aPV is required and its implementation feasibility would need to be assessed.

Our study has several limitations. First, most of the recruited children were vaccinated in a timely manner and probably do not reflect general Iranian children. However, this study shows that vaccination program is effective and that 2<sup>nd</sup> booster vaccination is appropriate, regardless of compliance. Second, no information was gathered regarding pertussis-related

symptoms that children may have experienced in the past year. This would have been interesting as occurrence of asymptomatic or mildly symptomatic infections in vaccinated individuals is greatly discussed [39]. However, questioning about history of clinical symptoms suffers from memory biases in such study design and may lead to wrong interpretations.

## Conclusions

This study shows that *B. pertussis* is circulating among children and adolescents in Tehran, despite very good compliance with the national immunization schedule observed herein. Anti-PT humoral immune response induced by the SII wPV waned over time after the 18-months booster injection and support WHO recommendations in implementing a booster in pre-school children [1]. Furthermore, an additional booster injection could be needed to reduce the circulation of *B. pertussis* in adolescents.

## Supporting information

**S1 Table. General description of the study population stratified by age category.** Values are shown as n (%).

(TIF)

**S2 Table. Distribution of anti-PT IgG levels by timespan since 2<sup>nd</sup> booster dose among fully vaccinated individuals.** Anti-PT IgG levels are shown using <LLOQ, [5–40[, [40–100 [and  $\geq 100$  IU/ml cut-offs, and the  $\geq 40$  IU/ml cut-off alone to include all anti-PT positive individuals. Anti-PT IgG titers are shown as n (%).

(TIF)

## Acknowledgments

We thank all the children and parents who kindly agreed to participate to this study, and staff from educational institutions. We also thank Ms. Sandra Corre who participated to laboratory staff training, study implementation and monitoring.

## Author Contributions

**Conceptualization:** Mohand Ait-Ahmed, Nicole Guiso, Fabien Taieb.

**Data curation:** Gaelle Noel, Farzad Badmasti, Vajihe S. Nikbin, David Tavel.

**Formal analysis:** Gaelle Noel, Farzad Badmasti, Vajihe S. Nikbin, Yoann Madec, Fabien Taieb.

**Investigation:** Farzad Badmasti, Seyed M. Zahraei, Fereshteh Shahcheraghi.

**Methodology:** Seyed M. Zahraei, Yoann Madec, Mohand Ait-Ahmed, Nicole Guiso, Fabien Taieb.

**Supervision:** Nicole Guiso, Fereshteh Shahcheraghi, Fabien Taieb.

**Validation:** Gaelle Noel, Nicole Guiso, Fabien Taieb.

**Writing – original draft:** Gaelle Noel.

**Writing – review & editing:** Gaelle Noel, Seyed M. Zahraei, Yoann Madec, Mohand Ait-Ahmed, Nicole Guiso, Fereshteh Shahcheraghi, Fabien Taieb.

## References

1. WHO. Pertussis vaccines: WHO position paper Wkly Epidemiol Rec 2015;. August 2015; 90:433–58.
2. Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global burden of pertussis in children younger than 5 years: a modelling study. *The Lancet Infectious Diseases*. 2017; 17(9):974–80. [https://doi.org/10.1016/S1473-3099\(17\)30390-0](https://doi.org/10.1016/S1473-3099(17)30390-0) PMID: 28623146
3. Zepp F, Heining U, Mertsola J, Bernatowska E, Guiso N, Roord J, et al. Rationale for pertussis booster vaccination throughout life in Europe. *The Lancet Infectious Diseases*. 2011; 11(7):557–70. [https://doi.org/10.1016/S1473-3099\(11\)70007-X](https://doi.org/10.1016/S1473-3099(11)70007-X) PMID: 21600850
4. Guiso N, de La Rocque F, Njamkepo E, Lécuyer A, Levy C, Romain O, et al. Pertussis Surveillance in Private Pediatric Practices, France, 2002–2006. *Emerging Infectious Disease journal*. 2008; 14(7):1159.
5. Pebody RG, Gay NJ, Giammanco A, Baron S, Schellekens J, Tischer A, et al. The seroepidemiology of *Bordetella pertussis* infection in Western Europe. *Epidemiology and Infection*. 2005; 133(1):159–71. <https://doi.org/10.1017/s0950268804003012> PMID: 15724723
6. Grimprel E, Bégue P, Anjak I, Njamkepo E, François P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. *Clinical and Diagnostic Laboratory Immunology*. 1996; 3(1):93–7. PMID: 8770511
7. Guiso N, Taieb F. Pertussis in Low and Medium Income Countries: A Pragmatic Approach. *Advances in Experimental Medicine and Biology*. 2019(0065–2598 (Print)).
8. WHO, editor. Immunological basis for immunization: Pertussis (2017 update) November 2017.
9. von Koenig CHW, Guiso N. Global burden of pertussis: signs of hope but need for accurate data. *The Lancet Infectious Diseases*. 2017; 17(9):889–90. [https://doi.org/10.1016/S1473-3099\(17\)30357-2](https://doi.org/10.1016/S1473-3099(17)30357-2) PMID: 28623145
10. Moradi-Lakeh M, Esteghamati A. National Immunization Program in Iran: whys and why not. *Human vaccines & immunotherapeutics*. 2013; 9(1):112–4.
11. Pourakbari B, Moradi B, Mirzaee F, Mahmoudi S, Teymuri M, Mamishi S. Seroprevalence of antibodies to diphtheria, tetanus and pertussis among healthy adolescents and adults in Iran. *Roumanian archives of microbiology and immunology*. 2013; 72(4):250–4. PMID: 24923108
12. Shamsizadeh A, Nikfar R, Yusefi H, Abbasi-Montazeri E, Cheraghian B. Seroprevalence of pertussis antibodies in 6-17-year-old students in Ahvaz, south-west Islamic Republic of Iran. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihyah li-sharq al-mutawassit*. 2014; 20(10):623–6.
13. WHO. Laboratory manual for the diagnosis of whooping cough caused by *Bordetella pertussis*/*Bordetella parapertussis*. 2014
14. WHO. Global and Regional Immunization Profile. WHO vaccine-preventable disease monitoring system. 2018.
15. Sadeghpour Heravi F, Nikbin VS, Nakhost Lotfi M, Badiri P, Jannesar Ahmadi N, Zahraei SM, et al. Strain variation and antigenic divergence among *Bordetella pertussis* circulating strains isolated from patients in Iran. *European Journal of Clinical Microbiology & Infectious Diseases*. 2018; 37(10):1893–900.
16. Sedaghat M, Nakhost Lotfi M, Talebi M, Saifi M, Pourshafie MR. Status of Pertussis in Iran. *Jundishapur Journal of Microbiology*. 2014; 7(11):e12421. <https://doi.org/10.5812/jjm.12421> PMID: 25774274
17. Guiso N, Berbers G, Fry NK, He Q, Riffelmann M, Wirsing von König CH, et al. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. *European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology*. 2011; 30(3):307–12.
18. Kurova N, Timofeeva E, Guiso N, Macina D. A cross-sectional study of *Bordetella pertussis* seroprevalence and estimated duration of vaccine protection against pertussis in St. Petersburg, Russia. *Vaccine*. 2018.
19. Barkoff A-M, Gröndahl-Yli-Hannuksela K, He Q. Seroprevalence studies of pertussis: what have we learned from different immunized populations. *Pathogens and Disease*. 2015; 73(7):ftv050–ftv. <https://doi.org/10.1093/femspd/ftv050> PMID: 26208655
20. Scott S, van der Sande M, Faye-Joof T, Mendy M, Sanneh B, Barry Jallow F, et al. Seroprevalence of pertussis in the Gambia: evidence for continued circulation of *bordetella pertussis* despite high vaccination rates. *The Pediatric infectious disease journal*. 2015; 34(4):333–8. <https://doi.org/10.1097/INF.0000000000000576> PMID: 25764094

21. Arefi Z, Kazemi Z, Shaahmadi Z, Mahmoudi S, Shaahmadi F. The Trend of the Extended Program of Immunization (EPI) in Iran from the Beginning (1984) to 2013. *International Journal of Pediatrics*. 2015; 3(4.1):717–23.
22. Riffelmann M, Thiel K, Schmetz J, Wirsing von Koenig CH. Performance of Commercial Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to *Bordetella pertussis*. *Journal of Clinical Microbiology*. 2010; 48(12):4459–63. <https://doi.org/10.1128/JCM.01371-10> PMID: 20943873
23. Wirsing von Konig CH, Gounis D, Laukamp S, Bogaerts H, Schmitt HJ. Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. *Eur J Clin Microbiol Infect Dis*. 1999; 18(5):341–5. <https://doi.org/10.1007/pl00015016> PMID: 10421041
24. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, Elvers LH, Berbers GA, van Der Zee A, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with *Bordetella pertussis*. *Journal of clinical microbiology*. 2000; 38(2):800–6. <https://doi.org/10.1128/JCM.38.2.800-806.2000> PMID: 10655388
25. WHO. WHO vaccine-preventable diseases: monitoring system. 2018 global summary 2018 [updated 22-Oct-2018. Available from: [http://apps.who.int/immunization\\_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=IRN&commit=OK#](http://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=IRN&commit=OK#).
26. Sedighi I, Karimi A, Amanati A. Old Disease and New Challenges: Major Obstacles of Current Strategies in the Prevention of Pertussis. *Iran J Pediatr*. 2016; 26(4):e5514. <https://doi.org/10.5812/ijp.5514> PMID: 27729960
27. Rejali M, Mohammadbeigi A, Mokhtari M, Zahraei SM, Eshtrati B. Timing and delay in children vaccination; evaluation of expanded program of immunization in outskirts of Iranian cities. *JRHS*. 2015; 15(1):54–8. PMID: 25821027
28. Poorolajal J, Khazaei S, Kousehlou Z, Bathaei S, Zahiri A. Delayed Vaccination and Related Predictors among Infants. *Iranian journal of public health*. 2012; 41(10):65–71. PMID: 23304664
29. Tauli MdC, Sato APS, Waldman EA. Factors associated with incomplete or delayed vaccination across countries: A systematic review. *Vaccine*. 2016; 34(24):2635–43. <https://doi.org/10.1016/j.vaccine.2016.04.016> PMID: 27109562
30. Khan J, Shil A, Prakash R. Exploring the spatial heterogeneity in different doses of vaccination coverage in India. *PloS one*. 2018; 13(11):e0207209–e. <https://doi.org/10.1371/journal.pone.0207209> PMID: 30485291
31. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. *Vaccine*. 2003; 21(17):2003–14.
32. Guiso N, Levy C, Romain O, Guillot S, Werner A, Rondeau MC, et al. Whooping cough surveillance in France in pediatric private practice in 2006–2015. *Vaccine*. 2017; 35(45):6083–8. <https://doi.org/10.1016/j.vaccine.2017.09.072> PMID: 28974408
33. Berbers GAM, van de Wetering MSE, van Gageldonk PGM, Schellekens JFP, Versteegh FGA, Teunis PFM. A novel method for evaluating natural and vaccine induced serological responses to *Bordetella pertussis* antigens. *Vaccine*. 2013; 31(36):3732–8. <https://doi.org/10.1016/j.vaccine.2013.05.073> PMID: 23742995
34. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine. *New England Journal of Medicine*. 1996; 334(6):349–56. <https://doi.org/10.1056/NEJM199602083340602> PMID: 8538705
35. Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SGF. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. *The Journal of Pediatrics*. 1998; 132(6):983–8. [https://doi.org/10.1016/s0022-3476\(98\)70395-6](https://doi.org/10.1016/s0022-3476(98)70395-6) PMID: 9627590
36. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to *Bordetella pertussis*. *Vaccine*. 1998; 16(20):1907–16. [https://doi.org/10.1016/s0264-410x\(98\)00227-8](https://doi.org/10.1016/s0264-410x(98)00227-8) PMID: 9796042
37. Edwards KM, Berbers GAM. Immune Responses to Pertussis Vaccines and Disease. *The Journal of Infectious Diseases*. 2014; 209(suppl\_1):S10–S5.
38. Campbell H, Gupta S, Dolan GP, Kapadia SJ, Kumar Singh A, Andrews N, et al. Review of vaccination in pregnancy to prevent pertussis in early infancy. *Journal of Medical Microbiology*. 2018; 67(10):1426–56. <https://doi.org/10.1099/jmm.0.000829> PMID: 30222536
39. Althouse BM, Scarpino SV. Asymptomatic transmission and the resurgence of *Bordetella pertussis*. *BMC medicine*. 2015; 13:146–146. <https://doi.org/10.1186/s12916-015-0382-8> PMID: 26103968